Amorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease
Neurol 64:392-393, Pot, C., et al, 2005
Catechol-O-Methyltransferase Inhibitors for Treatment of Parkinson's Disease
Lancet 351:1221-1222, Nutt,J.G., 1998
A randomized,Double-blind,Placebo-Controlled Trial of Subcutaneously Injected Apomorphine for Parkinsonian Off-State Events
Arch Neurol 58:1385-1392, Dewey,R.B.,et al, 2001
Subcutaneous Apomorphine in Parkinson's Disease
Effective Yet Underused, BMJ 316:6411998., , 1998
Extrapyramidalism in Alzheimer's Disease:Prevalence, Psychiatric and Neuropsychological Correlates
JNNP 57:1503-1509, Merello,M.,et al, 1994
Intranasal Apomorphine in Parkinsonian On-Off Fluctuations
Arch Neurol 49:482-484, vanLaar,T.,et al, 1992
Intranasal Apomorphine in Parkinson's Disease
Neurol 41:761-762, Kleedorfer,B.,et al, 1991
Subcutaneous Apomorphine in the Treatment of Parkinson's Disease
JNNP 53:96-101, Frankel,J.P.,et al, 1990
Subcutaneous Apomorphine in Parkinsonian On-Off Oscillations
Lancet 1:403-406, Stibe,C.M.H.,et al, 1988
Role of Subcutaneous Apomorphine in Parkinsonian Voiding Dysfunction
Lancet 2:1451-1453, Christmas,T.J.,et al, 1988
123I-iodobenzamide-SPECT Predicts Dopaminergic Responsiveness in patients with De Dovo Parkinsonism
Neurol 42:556-561, Schwarz,J.,et al, 1992
Challenge Tests to Predict the Dopaminergic Response in Untreated Parkinson's Disease
Neurol 41:1723-1725, Highes,A.J.,et al, 1991
Apomorphine Hydrochloride-Induced Improvement in Huntington's Chorea
Arch Neurol 35:27, Corsini,G.U.,et al, 1978